ArticleInquiry : a journal of medical care organization, provision and financing
Balancing Scientific and Commercial Interests: The European Health Data Space Response to Commercial Scientific Research.
Article in Inquiry : a journal of medical care organization, provision and financing. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tele-Oncology in the Post-Pandemic Era: Clinical Integration, Access Disparities and Medico-Legal Accountability.Current oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Commercial interests have increasingly engaged in scientific research, particularly as the European Health Data Space (EHDS) allows access to electronic health records for such studies. Normative legal research was conducted to examine EU Member States' effective medical research legislation and landmark cases. Eleven EU Member States' legislation do not reference commercial medical research. Regarding the others, some adopt stricter rules for commercial research. Others prioritize incentives for non-commercial research. Related legislation primarily regulates research based on funding sources, diverging from the multi-actor and multi-interest nature of health data research. Both the GDPR and ethical guidelines generally exempt anonymized data from oversight, creating a governance gap. Low marginal costs and the black-box nature of data-driven approaches further intensify funding biases, potentially undermining public trust. Member States also differ in data subjects' right to opt out of scientific research. Such regulatory fragmentation undermines EHDS implementation and creates opportunities for regulatory arbitrage. Commercial scientific research should be understood as a type of research conducted by profit-driven actors through ongoing business operations. Special measures should be applied to commercial scientific research within the EHDS, including mandatory consideration reflecting data market pricing, tiered data dividends, compulsory health data access body ethical review, conflicts of interest declaration, and opt-out rights for data subjects. Rules for providing data access are tailored to the stage of research and require a balancing test between research interests and trade secrets. Raw data should be made accessible. Processed data should be made available when classified as essential. Research results should always be provided. A centralized EU platform is recommended to reduce administrative burdens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.